Risk of major adverse cardiovascular events in CYP2C19 LoF genotype guided clopidogrel against alternative antiplatelets for CAD patients undergoing PCI : Meta‐analysis
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70080 ↗At a glance
Metaanalyse in Clinical and Translational Science, 2025. Written by Mohitosh Biswas and 4 co-authors. Institution: Department of Pharmacy, University of Rajshahi, Rajshahi, Bangladesh. Major MEDLINE topics: Cytochrome P-450 CYP2C19, Clopidogrel, Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention. Cited 7 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Selection of rational antagonists of P2Y 12 receptor for CAD patients who inherit CYP2C19 LoF alleles remains still conflicting. This study compared the clinical outcomes in CAD patients inheriting CYP2C19 LoF alleles undergoing PCI and treated with clopidogrel against alternative antagonists of P2Y 12 receptor. A thorough literature search was performed across multiple scientific databases following the PRISMA guidelines and PICO model. Setting the statistical significance at p < 0.05 and RevMan software was used to calculate the risk ratios (RRs). Estimation of the pooled analysis revealed a significant 62% increased risk of major adverse cardiovascular events (MACE) in CAD patients inheriting CYP2C19 LoF alleles and treated with clopidogrel against those treated with alternative P2Y 12 receptor antagonists such as prasugrel or ticagrelor (RR 1.62; 95% CI 1.42–1.86; p < 0.00001). In addition, Asian CAD patients were found at a significantly higher risk of MACE (RR 1.93; 95% CI: 1.49–2.49; p < 0.00001) juxtaposed to CAD patients of other ethnicities (RR 1.51; 95% CI: 1.29–1.78; p < 0.00001). Conversely, between these two treatment groups, taking clopidogrel against prasugrel/ticagrelor, who possess CYP2C19 LoF alleles, no significant differences in bleeding events were observed (RR 0.94; 95% CI 0.79–1.11; p = 0.47). CAD patients undergoing PCI who inherited CYP2C19 LoF alleles and treated with clopidogrel were associated with significantly higher risk of MACE against those treated with alternative antagonists of P2Y 12 receptor, that is, prasugrel or ticagrelor.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Pharmacy, University of Rajshahi, Rajshahi, Bangladesh.
- Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Laboratory for Pharmacogenomics, Ramathibodi Hospital, Somdech Phra Debaratana Medical Center SDMC, Bangkok, Thailand.
- Department of Pharmacy, Daffodil International University, Dhaka, Bangladesh.
- The Preventive Genomics & Family Check-Up Services Center, Bumrungrad International Hospital, Pharmacogenomics and Precision Medicine Clinic, Bangkok, Thailand.
- MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
ORCID profiles: Mohitosh Biswas, Murshadul Alam Murad, Most Sumaiya Khatun Kali, Chonlaphat Sukasem
Cite
APA
Biswas, M., Murad, M. A., Ershadian, M., Kali, M. S. K., & Sukasem, C. (2025). Risk of major adverse cardiovascular events in CYP2C19 LoF genotype guided clopidogrel against alternative antiplatelets for CAD patients undergoing PCI : Meta‐analysis. Clinical and Translational Science. https://doi.org/10.1111/cts.70080
Vancouver
Biswas M, Murad MA, Ershadian M, Kali MSK, Sukasem C. Risk of major adverse cardiovascular events in CYP2C19 LoF genotype guided clopidogrel against alternative antiplatelets for CAD patients undergoing PCI : Meta‐analysis. Clinical and Translational Science. 2025. doi:10.1111/cts.70080
BibTeX
@article{Biswas2025,
author = {Biswas, Mohitosh and Murad, Murshadul Alam and Ershadian, Maliheh and Kali, Most Sumaiya Khatun and Sukasem, Chonlaphat},
title = {Risk of major adverse cardiovascular events in CYP2C19 LoF genotype guided clopidogrel against alternative antiplatelets for CAD patients undergoing PCI : Meta‐analysis},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70080}
}
EUVIMED